{
    "id": 26322,
    "fullName": "ALK F1245V",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ALK F1245V lies within the protein kinase domain of the Alk protein (UniProt.org). F1245V confers a gain of function to the Alk protein, as it results in increased Alk kinase activity in vitro and leads to transformation activity in cell culture (PMID: 25517749).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 4535,
                    "pubMedId": 25517749,
                    "title": "ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25517749"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "F1245V",
    "createDate": "04/13/2017",
    "updateDate": "11/21/2019",
    "referenceTranscriptCoordinates": {
        "id": 102028,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29213994A>C",
        "cDna": "c.3733T>G",
        "protein": "p.F1245V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10489,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in a partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697).",
            "molecularProfile": {
                "id": 27527,
                "profileName": "ALK F1245V"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8566,
                    "pubMedId": 28183697,
                    "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27527,
            "profileName": "ALK F1245V",
            "profileTreatmentApproaches": [
                {
                    "id": 19768,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK F1245V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102028,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29213994A>C",
            "cDna": "c.3733T>G",
            "protein": "p.F1245V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}